Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228282 | 0.82 | USP2 (0.49) | MAPK1USP2SMN1; SMN2GPR119POLB | |
| SCHEMBL8286 | 0.82 | USP2 (0.58) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| SCHEMBL1225127 | 0.82 | USP2 (0.58) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| SCHEMBL587550 | 0.82 | USP2 (0.58) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| SCHEMBL12005408 | 0.82 | USP2 (0.58) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| Pyridine SCHEMBL28276860 | 0.81 | MAPK1 (0.49) | MAPK1USP2SMN1; SMN2GPR119POLB | |
| Benzene SCHEMBL29155321 | 0.80 | USP2 (0.53) | MAPK1USP2SMN1; SMN2GPR119POLB | |
| Ammonia Solution, Strong SCHEMBL18035416 | 0.80 | USP2 (0.56) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| SCHEMBL14653343 | 0.80 | USP2 (0.56) | MAPK1USP2SMN1; SMN2GPR119KDM4E | |
| Hydrochloric Acid SCHEMBL4141237 | 0.80 | USP2 (0.56) | MAPK1USP2SMN1; SMN2GPR119KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604025-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-8367661-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8202859-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | CYTOKINETICS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8101620-B2 | Heterocyclic sulfonamides | CYTOKINETICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1605752-B1 | Sulfonamides for the treatment of congestive heart failure, their compositions and uses. | CYTOKINETICS INC (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110112154-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2011-05-12 | — | — | US | disclosed |
| US-7888373-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7595322-B2 | Heterocyclic sulfonamides as modulators of cardiac sarcomeres | CYTOKINETICS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1605752-A4 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-05-07 | — | — | EP | disclosed |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | CYTOKINETICS, INCORPORATED | 2007-04-05 | — | — | US | disclosed |
| EP-1605752-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004086865-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267537-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | MAPK1 3460/4885USP2 1049/4885SMN1; SMN2 293/4885 |
| US-20100069370-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TNNI3, TNNT2, MYLK2 | MAPK1 3487/4885USP2 2137/4885SMN1; SMN2 185/4885 |
| US-20070078126-A1 | Useful in selective modulation of cardiac sarcomere, for example, by potentiating cardiac myosin; can be used to treat heart failure including CHF, particularly systolic heart failure; 4-[4-chloro-3-(5-phenyl-[1,3,4]thiadiazol-2-ylcarbamoyl)-benzenesulfonyl]-piperazine-1-carboxylic acid ethyl ester | MYLK2, MYH2, MYH14 | MAPK1 2485/4885USP2 1402/4885SMN1; SMN2 664/4885 |
| US-20120232092-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | MAPK1 3460/4885USP2 1049/4885SMN1; SMN2 293/4885 |
| US-20110112154-A1 | Compounds, compositions and methods | TNNI3, TNNT2, MYLK2 | MAPK1 3487/4885USP2 2137/4885SMN1; SMN2 185/4885 |
| US-20120088779-A1 | HETEROCYCLIC SULFONAMIDES | TNNI3, TNNT2, MYLK2 | MAPK1 3460/4885USP2 1049/4885SMN1; SMN2 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.